Placeholder Banner

New CMS Reimbursement Rule “Reaffirms the Many Benefits of Transformational Therapies”

September 2, 2020
Media Contact
Brian Newell

Today, the Centers for Medicare and Medicaid Services finalized this year’s inpatient prospective payment system (IPPS) rule, which includes a new diagnosis-related group (DRG) to streamline reimbursements for providers administering CAR T-cell therapies to patients with cancer.

Following CMS’ announcement, BIO’s Executive Vice President for Health Policy, Dan Durham, said the following:

“This final rule reaffirms the many benefits transformational therapies – such as CAR T-cell therapy -- provide patients and society more broadly. Medicare reimbursement should not serve as a barrier to life-saving treatments, and the final policy announced today validates this basic principle. It’s vital the Trump administration continue to build on these steps to ensure that seniors benefit from the next generation of innovative cures and treatments, including CAR T-cell therapy.”

Discover More
Dr. Michelle McMurry-Heath, the president and CEO of the Biotechnology Innovation Organization (BIO), released a letter today urging Health and Human Services (HHS) Secretary Alex Azar to “publicly release all new guidance developed by the Food and…
In a new video, Cynthia Bens, patient advocate and Senior Vice President of Public Policy at the Personalized Medicine Coalition, shares her views on how adopting foreign price controls for prescription medicines will impact patients in the U.S. …
In a new video, Alex Karnal, a life science investor and partner at Deerfield Management, shares why investing in new cures and treatments is personal, and he explains how President Trump’s plan to import foreign price controls would have an …